Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus oral antidepressant in treatment-resistant depression
NCT03434041Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03434041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434041.